However, it has been reported that nearly all 1p/19q codeleted glioma has IDH1 mutation [60]; therefore, such biomarkers can be represented by the gene expression of IDH1 in a mediate manner, although the mutation cannot be directly detected. The gene discussed is IDH1; the disease is central nervous system cancer.